Lymphoma (follicular non-Hodgkin's) - rituximab (replaced by TA137)

Summary

This guidance has been updated and replaced by Lymphoma (follicular non-Hodgkin's) - rituximab.

Documents

For healthcare professionals

• TA37 Lymphoma (follicular non-Hodgkin's) - rituximab: Summary
• TA37 Lymphoma (follicular non-Hodgkin's) - rituximab: Guidance

For patients, carers and the public

• TA37 Lymphoma (follicular non-Hodgkin's) - rituximab: Information for the public

Background information

• Review decision
• Assessment report for riituximab for follicular non-Hodgkin's lymphoma (pdf)
• 2002/018 NICE recommends the selective use of rituximab for follicular non-Hodgkins lymphoma
• Appraisal rituximab for follicular lymphoma - Summary Appeal Decision

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

• None found